Sanofi (SNY) Receivables - Other (2015 - 2025)

Sanofi has disclosed Receivables - Other across 11 years of filings, most recently posting $684.5 million for Q4 2025.

• Receivables - Other for Q4 2025 came in at $684.5 million, up 248.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $684.5 million (up 248.11% YoY), and the FY2025 annual result was $684.5 million, up 248.11% from the prior year.
• Receivables - Other came in at $684.5 million for Q4 2025 at Sanofi, up from $196.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.6 billion in Q4 2023 to a low of $196.6 million in Q4 2024.
• The 5-year median for Receivables - Other is $684.5 million (2025), against an average of $739.3 million.
• Across the five-year window, Receivables - Other surged 1444.75% in 2021 and tumbled 87.38% in 2024, its largest moves.
• Sanofi's Receivables - Other stood at $920.9 million in 2021, then sank by 63.44% to $336.7 million in 2022, then jumped by 362.74% to $1.6 billion in 2023, then tumbled by 87.38% to $196.6 million in 2024, then jumped by 248.11% to $684.5 million in 2025.
• The last three Receivables - Other figures came in at $684.5 million (Q4 2025), $196.6 million (Q4 2024), and $1.6 billion (Q4 2023), per Business Quant data.